Dyne Therapeutics Inc
Ownership
Ownership Structure
Who owns Dyne Therapeutics Inc (DYN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.7% of the shares are freely tradable; institutional investors hold 115.5%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 16.49 | 30,785,801 | +50.8 | 03/31/2026 |
| HHG PLC | 7.31 | 13,647,376 | -1.7 | 03/31/2026 |
| BlackRock Inc | 6.27 | 11,699,870 | +4.5 | 03/31/2026 |
| FMR Inc | 4.77 | 8,908,980 | +35.6 | 03/31/2026 |
| Atlas Venture Life Science Advisors, LLC | 3.64 | 6,800,099 | -25.5 | 06/30/2026 |
| Orbis Allan Gray Ltd | 3.62 | 6,762,231 | +40.8 | 03/31/2026 |
| State Street Corp | 3.56 | 6,653,746 | -0.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.43 | 6,405,069 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 3.95 | 7,380,345 | +5.4 | 07/31/2026 |
| T. Rowe Price US Small-Cap Core Equity | 3.75 | 7,004,602 | -0.1 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Kersten Dirk | Director | 3,586,796 | 64,921,008 $ | Jul 27, 2026 | indirect |
| Rhodes Jason P | Director | 428,946 | 7,763,923 $ | Aug 14, 2026 | indirect |
| Cox John | CEO & President | 357,507 | 6,470,877 $ | Sep 8, 2026 | direct |
| Kerr Douglas | Chief Medical Officer | 162,564 | 2,942,408 $ | Sep 8, 2026 | direct |
| Friedl-Naderer Johanna | Chief Commercial Officer | 152,897 | 2,767,436 $ | Sep 8, 2026 | direct |
| Lucera Erick | Chief Financial Officer | 119,766 | 2,167,765 $ | Aug 13, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 185 | 18.88 | 3,493 |
| Sep 8, 2026 | Kerr Douglas | Chief Medical Officer | Sell | 1,290 | 18.88 | 24,355 |
| Sep 8, 2026 | Cox John | CEO & President | Sell | 5,658 | 18.88 | 106,823 |
| Sep 4, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 900 | 24.35 | 21,915 |
| Sep 4, 2026 | Kerr Douglas | Chief Medical Officer | Sell | 3,745 | 24.35 | 91,191 |
| Aug 14, 2026 | Rhodes Jason P | Director | Sell | 322,465 | 25.00 | 8,061,625 |
| Aug 14, 2026 | Rhodes Jason P | Director | Sell | 478,377 | 25.00 | 11,959,425 |
| Aug 14, 2026 | Rhodes Jason P | Director | Sell | 1,359,674 | 25.00 | 33,991,850 |
| Aug 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 226 | 26.28 | 5,939 |
| Aug 13, 2026 | Kerr Douglas | Chief Medical Officer | Sell | 1,556 | 26.28 | 40,892 |
| Aug 13, 2026 | Lucera Erick | Chief Financial Officer | Sell | 1,797 | 26.28 | 47,225 |
| Aug 13, 2026 | Rhodes Jason P | Director | Sell | 63,643 | 26.20 | 1,667,447 |
| Aug 13, 2026 | Rhodes Jason P | Director | Sell | 94,415 | 26.20 | 2,473,673 |
| Aug 13, 2026 | Rhodes Jason P | Director | Sell | 268,354 | 26.20 | 7,030,875 |
| Aug 13, 2026 | Cox John | CEO & President | Sell | 4,986 | 26.28 | 131,032 |
| Jul 27, 2026 | Kersten Dirk | Director | Sell | 5,388 | 26.04 | 140,319 |
| Jul 27, 2026 | Kersten Dirk | Director | Sell | 256,072 | 25.50 | 6,530,451 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 5,000 | 23.61 | 118,050 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 11,665 | 23.62 | 275,527 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 49,193 | 23.17 | 1,139,802 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 14,844 | 23.62 | 350,615 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 62,543 | 23.17 | 1,449,121 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 29,587 | 23.62 | 698,845 |
| Jul 7, 2026 | Rhodes Jason P | Director | Sell | 124,379 | 23.17 | 2,881,861 |
| Jul 6, 2026 | Rhodes Jason P | Director | Sell | 100,019 | 22.79 | 2,279,433 |
| Jul 6, 2026 | Rhodes Jason P | Director | Sell | 127,182 | 22.79 | 2,898,478 |
| Jul 6, 2026 | Rhodes Jason P | Director | Sell | 253,039 | 22.79 | 5,766,759 |
| Apr 22, 2026 | Jason P Rhodes | Director | Sell | 287,956 | 19.68 | 5,666,974 |
| Apr 21, 2026 | Jason P Rhodes | Director | Sell | 274,297 | 19.52 | 5,354,277 |
| Apr 20, 2026 | Jason P Rhodes | Director | Sell | 272,049 | 20.06 | 5,457,303 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.